Piper Sandler has recently raised CytomX Therapeutics Inc (CTMX) stock to Overweight rating, as announced on May 28, 2024, according to Finviz. Earlier, on May 9, 2024, Wedbush had raised the stock from a Neutral to Outperform, setting a price target of $8. Jefferies also raised Buy rating with a price target of $8. Additionally, JP Morgan raised Neutral rating on April 22, 2024. BMO Capital Markets analysts, in their report published on November 14, 2022, also reduced Market Perform rating and set a price target of $2.60 for CytomX Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
CytomX Therapeutics Inc (CTMX) Stock Trading Recap
On Monday, CytomX Therapeutics Inc (CTMX) stock saw a decline, ending the day at $1.04 which represents a decrease of $-0.05 or -4.59% from the prior close of $1.09. The stock opened at $1.08 and touched a low of $0.98 during the day, reaching a high of $1.1. The volume of shares traded was 2.60 million exceeding the average volume of 0.75 million.
CTMX Stock Performance and Moving Averages
In recent trading, CytomX Therapeutics Inc (CTMX) stock price has shown some volatility, fluctuating 2.97% over the last five trades and -9.57% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -44.97%, and it has plunged by -10.34% in the previous three months. Currently, CTMX is trading at -2.21%, -8.50%, and -35.56% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, CTMX, a Healthcare sector stock, is trading -82.22% below its 52-week high but remains 6.11% above its 52-week low. The Average True Range (ATR) (14 days) of 0.07 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
CytomX Therapeutics Inc’s Profitability and Valuation Ratios
CytomX Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 5.30% and a profit margin of 10.92%, with a gross margin of -44.97%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, CytomX Therapeutics Inc’s market capitalization stands at $88.71 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 6.13, assessing the company’s valuation relative to its earnings. Additionally, the Price-to-Sales Ratio is 0.7, reflecting the market’s valuation of the company’s sales.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.69% of CytomX Therapeutics Inc (CTMX)’s shares, while financial institutions hold 72.44%.